{'fraction_non_alphanumeric': 0.024390243902439025, 'fraction_numerical': 0.0, 'mean_word_length': 6.565789473684211, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin–tazobactam

Vancomycin is very commonly used in combination with piperacillin–tazobactam (PTZ) as the initial empiric treatment for moderate–severe infection, whenever coverage for both methicillin‐resistant Staphylococcus aureus and Pseudomonas aeruginosa is required. The combination of vancomycin and PTZ in adults has recently been reported to significantly increase the risk of acute kidney injury (AKI) relative to vancomycin monotherapy; such reports in pediatrics, however, are sparse.